Development and application of drug-induced liver injury surveillance and assessment system
- VernacularTitle:药物性肝损伤自动监测与评估系统的研发与应用
- Author:
Chao AI
1
;
Zhaoshuai JI
1
;
Yaxin ZHANG
1
;
An LIU
1
;
Xuesi ZHOU
2
;
Zhonghao CHEN
2
;
Ji WU
2
Author Information
1. Dept. of Pharmacy，Beijing Tsinghua Changgung Hospital （BTCH） Affiliated to Tsinghua University/School of Clinical Medicine，Tsinghua University，Beijing 102218，China
2. Dept. of Electronic Engineering，Tsinghua University，Beijing 100084，China
- Publication Type:Journal Article
- Keywords:
drug-induced liver injury;
natural language processing;
surveillance and assessment system;
adverse drug
- From:
China Pharmacy
2023;34(19):2409-2413
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish the drug-induced liver injury （DILI） surveillance and assessment system （DILI-SAS）， and to improve the diagnostic efficiency of clinical DILI. METHODS The DILI-SAS was constructed by using natural language processing technology to mine and utilize all inpatient medical record data， and combined with Roussel Uclaf causality assessment method （RUCAM）. The medical records of 19 445 hospitalized patients from August 2022 to January 2023 were detected to verify the performance of the system and manually analyze the basic data of patients with DILI and the distribution of the first suspected drugs. RESULTS The overall accuracy rate of the DILI-SAS system was 91.95%， and the recall rate was 93.20%. Seventy-five DILI cases were detected， and the DILI incidence rate was 385.70/100 000 people. The efficiency of DILI monitoring by human- computer coupling was increased by about 60 times of manual monitoring； males （61.33%） and patients over 60 years old （56.00%） were the most common in the 75 cases of DILI. The clinical type of liver injury was hepatocyte injury （69.33%）， the incubation period was mainly 5-90 days after treatment （62.67%）， and the RUCAM score between 3 and 5 was the most common （66.67%）； pharmacological distribution of the first suspected drugs was mainly dihydropyridines， HMG CoA reductase inhibitors， proton pump inhibitors， etc. The specific drugs were atorvastatin， omeprazole， ceftriaxone， metronidazole and other drugs. CONCLUSIONS The establishment of DILI-SAS can improve the evaluation efficiency on the basis of ensuring the accuracy degree， and provide a solution for the early identification， diagnosis and evaluation of clinical DILI.
